@article{article, title = {{Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).}}, publisher = {{American Society of Clinical Oncology (ASCO)}}, url = {{}}, year = {{2013}}, month = {{6}}, author = {{James ND and Pirrie S and Barton D and Brown JE and Billingham L and Collins SI and Daunton A and Birtle AJ and Chakraborti PR and Ford D and Hussain SA et al}}, doi = {{10.1200/jco.2013.31.18_suppl.lba5000}}, volume = {{31}}, journal = {{Journal of Clinical Oncology}}, issue = {{18_suppl}}, pages = {{LBA5000-LBA5000}}, note = {{Accessed on 2025/07/20}}}